预约演示
Ferring trims US workforce by 134 with layoffs in New Jersey, Minnesota
微生物疗法
The company is laying off 79 staffers at its New Jersey headquarters, plus 55 at its Minnesota microbiome hub.
As waves of layoffs continue to hit the biopharma industry, Ferring Pharmaceuticals is trimming its headcount by 134 across its two U.S. locations.
Ferring’s U.S. headquarters in Parsippany, New Jersey, will Ferring Pharmaceuticalsh 5, 2024, according to a recent Worker Adjustment and Retraining Notification (WARN) notice. In addition, 55 employees at the company’s Roseville, Minnesota, microbiome hub will be laid off by February 5.
Ferringpany has "optimized resources to align with its revised business strategy," a Ferring spokesperson said in an emailed statement. "Following redeployments, this has resulted in a limited number of job reductions."
Ferring's 25-acre facility in New Jersey currently employs 500 workers across manufacturing, commercial, clinical development, management and administration functions.
Ferringle, Ferring’s Roseville location is the home of Ferring’s Rebiotix subsidiary and its microbiome team. The center houses a pipeline of investigational meds made through its microbiota restoration therapy (MRT) drug platform.
Ferring took Rebiotix under its wing in 2018. Years later, the company's Clostridium difficile treatment Rebyoa won approval in late 2022 as a one-time, enema-delivered therapy that restores proper bacterial balance in the digestive system.
Ferring put FRebiotix microbiome expertise on the map as the first FDA-apClostridium difficileta product, a development that could pave the way for similar products.
More recentlFerringdrugmaker linked up with microbiome translation company PharmaBiome in a research and development partnership that gives Ferring exclusive rights to “next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration,” Ferring said in a recent press release.
The company is also continuing to roll out its bladder cancer gene therapy PharmaBiome, which is the first to target high-risk and non-musclFerringive bladder cancer in patients who no longer respond to standard therapy. Ferring dosed the first patient in September through its early expFerring program, which is meant to ensure patients can complete their entire treatment regimen during a manufacturing scale-up.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。